Fennec Pharmaceuticals Inc. (FENC)
$
5.91
-0.60 (-10.15%)
Key metrics
Financial statements
Free cash flow per share
-0.4001
Market cap
168.9 Million
Price to sales ratio
3.7657
Debt to equity
0
Current ratio
6.3402
Income quality
1.2805
Average inventory
2 Million
ROE
-2.3642
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company, focusing on innovative solutions for unmet medical needs. The weighted average number of diluted shares outstanding is 28,577,000.00 reflecting potential dilution effects on shareholder value. The company's operating expenses amount to $48,455,648.00 encompassing various operational costs incurred in its pursuit of advancing clinical candidates. The gross profit ratio is 0.92 which illustrates the efficiency of the company’s production and sales operations. In its financial disclosures, Fennec Pharmaceuticals reported depreciation and amortization expenses of $0.00 reflecting the wear and tear of its assets. Furthermore, the company reported an income before tax of -$10,274,770.00 showcasing its pre-tax profitability and underlying operational strength. With its clinical stage product candidate, PEDMARK, a formulation of sodium thiosulfate aimed at preventing platinum-induced ototoxicity in pediatric cancer patients, Fennec is committed to improving treatment outcomes in vulnerable populations. As a small-cap player with a market capitalization of $168,907,948.00 Fennec Pharmaceuticals is well positioned in the biopharmaceutical sector, contributing significantly to the overall market landscape. The stock is affordable at $8.67 making it suitable for budget-conscious investors looking for opportunities in emerging companies. However, the stock has a low average trading volume of 150,827.00 indicating lower market activity which might affect liquidity. As it belongs to the Healthcare sector, Fennec Pharmaceuticals is driving innovation and growth, establishing itself as a key player in the Biotechnology industry, shaping the future of therapeutic solutions. Investors who focus on this sector may find valuable prospects as the company navigates its clinical development and market strategies.
Is Fennec Pharmaceuticals Inc. (FENC) a good investment?
Investing in Fennec Pharmaceuticals Inc. (FENC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Fennec Pharmaceuticals Inc. (FENC)'s stock forecast?
Analysts predict Fennec Pharmaceuticals Inc. stock to fluctuate between $4.68 (low) and $9.92 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Fennec Pharmaceuticals Inc.'s market capitalization?
As of 2026-03-27, Fennec Pharmaceuticals Inc.'s market cap is $168,907,948, based on 28,580,025 outstanding shares.
How does Fennec Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Fennec Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Fennec Pharmaceuticals Inc. (FENC) stock?
To buy Fennec Pharmaceuticals Inc. (FENC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FENC. Place an order (Market, Limit, etc.).
What is the best time to invest in Fennec Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Fennec Pharmaceuticals Inc. stock ever split?
Fennec Pharmaceuticals Inc.'s last stock split was 1:3 on 2014-09-09.
How did Fennec Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $45,423,482 | EPS: -$0.36 | Growth: 2,150%.
Where can I find Fennec Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.fennecpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Fennec Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Fennec Pharmaceuticals Inc. stock?
All-time high: $11.92 (2023-12-28) | All-time low: $3.82 (2021-12-01).
What are the key trends affecting Fennec Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
newsfilecorp.com
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws.
seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
benzinga.com
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
zacks.com
Adherex Technologies (FENC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating
globenewswire.com
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).
defenseworld.net
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The
seekingalpha.com
Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast.
See all news
